[go: up one dir, main page]

GB202013024D0 - Sars-Cov-2 (SARS2, COVID-19) antobodies - Google Patents

Sars-Cov-2 (SARS2, COVID-19) antobodies

Info

Publication number
GB202013024D0
GB202013024D0 GBGB2013024.1A GB202013024A GB202013024D0 GB 202013024 D0 GB202013024 D0 GB 202013024D0 GB 202013024 A GB202013024 A GB 202013024A GB 202013024 D0 GB202013024 D0 GB 202013024D0
Authority
GB
United Kingdom
Prior art keywords
sars2
antobodies
covid
cov
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2013024.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Erasmus University Medical Center
Universiteit Utrecht Holding BV
Harbour Antibodies BV
Original Assignee
Erasmus University Medical Center
Universiteit Utrecht Holding BV
Harbour Antibodies BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erasmus University Medical Center, Universiteit Utrecht Holding BV, Harbour Antibodies BV filed Critical Erasmus University Medical Center
Priority to GBGB2015240.1A priority Critical patent/GB202015240D0/en
Publication of GB202013024D0 publication Critical patent/GB202013024D0/en
Priority to GBGB2101720.7A priority patent/GB202101720D0/en
Priority to PCT/EP2021/055683 priority patent/WO2021180602A1/en
Priority to TW110108025A priority patent/TW202200612A/en
Priority to US17/194,076 priority patent/US20210340225A1/en
Priority to UY0001039118A priority patent/UY39118A/en
Priority to PCT/EP2021/055693 priority patent/WO2021180604A1/en
Priority to US17/381,154 priority patent/US20220017606A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C07K16/102—
    • C07K16/104—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GBGB2013024.1A 2020-03-12 2020-08-20 Sars-Cov-2 (SARS2, COVID-19) antobodies Ceased GB202013024D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB2015240.1A GB202015240D0 (en) 2020-03-12 2020-09-25 SARS-Cov-2 (SARS2, COVID-19) Antibodies
GBGB2101720.7A GB202101720D0 (en) 2020-03-12 2021-02-08 Sars-cov-2 (sars2, covid-19) antibodies
PCT/EP2021/055683 WO2021180602A1 (en) 2020-03-12 2021-03-05 Sars-cov-2 (sars2, covid-19) antibodies
TW110108025A TW202200612A (en) 2020-03-12 2021-03-05 Sars-cov-2 (sars2, covid-19) antibodies
US17/194,076 US20210340225A1 (en) 2020-03-12 2021-03-05 Sars-cov-2 (sars2, covid-19) antibodies
UY0001039118A UY39118A (en) 2020-03-12 2021-03-05 ANTIBODIES AGAINST SARS-Cov-2 (SARS2, COVID-19)
PCT/EP2021/055693 WO2021180604A1 (en) 2020-03-12 2021-03-05 Sars-cov-2 (sars2, covid-19) antibodies
US17/381,154 US20220017606A1 (en) 2020-03-12 2021-07-20 Sars-cov-2(sars2, covid-19) antibodies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2003632.3A GB202003632D0 (en) 2020-03-12 2020-03-12 SARS-Cov-2 (SARS2, COVID-19) antibodies
GBGB2004340.2A GB202004340D0 (en) 2020-03-12 2020-03-25 SARS-Cov-2 (SARS2, COVID-19) Antibodies

Publications (1)

Publication Number Publication Date
GB202013024D0 true GB202013024D0 (en) 2020-10-07

Family

ID=70453696

Family Applications (5)

Application Number Title Priority Date Filing Date
GBGB2003632.3A Ceased GB202003632D0 (en) 2020-03-12 2020-03-12 SARS-Cov-2 (SARS2, COVID-19) antibodies
GBGB2004340.2A Ceased GB202004340D0 (en) 2020-03-12 2020-03-25 SARS-Cov-2 (SARS2, COVID-19) Antibodies
GBGB2013024.1A Ceased GB202013024D0 (en) 2020-03-12 2020-08-20 Sars-Cov-2 (SARS2, COVID-19) antobodies
GBGB2015240.1A Ceased GB202015240D0 (en) 2020-03-12 2020-09-25 SARS-Cov-2 (SARS2, COVID-19) Antibodies
GBGB2101720.7A Ceased GB202101720D0 (en) 2020-03-12 2021-02-08 Sars-cov-2 (sars2, covid-19) antibodies

Family Applications Before (2)

Application Number Title Priority Date Filing Date
GBGB2003632.3A Ceased GB202003632D0 (en) 2020-03-12 2020-03-12 SARS-Cov-2 (SARS2, COVID-19) antibodies
GBGB2004340.2A Ceased GB202004340D0 (en) 2020-03-12 2020-03-25 SARS-Cov-2 (SARS2, COVID-19) Antibodies

Family Applications After (2)

Application Number Title Priority Date Filing Date
GBGB2015240.1A Ceased GB202015240D0 (en) 2020-03-12 2020-09-25 SARS-Cov-2 (SARS2, COVID-19) Antibodies
GBGB2101720.7A Ceased GB202101720D0 (en) 2020-03-12 2021-02-08 Sars-cov-2 (sars2, covid-19) antibodies

Country Status (6)

Country Link
US (2) US20210340225A1 (en)
AR (1) AR121522A1 (en)
GB (5) GB202003632D0 (en)
TW (1) TW202200612A (en)
UY (1) UY39118A (en)
WO (2) WO2021180604A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
EP3947406A4 (en) 2019-04-05 2022-12-28 Academia Sinica SIALIDA-RESISTANT SACCHARIDE, AND PROCESSES FOR THE PREPARATION AND USE THEREOF
MY197648A (en) 2020-04-02 2023-06-30 Regeneron Pharma Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
CN113583114B (en) * 2020-04-30 2023-09-26 养生堂有限公司 Antibodies against SARS-CoV-2 and uses thereof
KR20230038416A (en) 2020-05-08 2023-03-20 아카데미아 시니카 Chimeric Influenza Vaccine
US20230220053A1 (en) * 2020-05-18 2023-07-13 Elpis Biopharmaceuticals ANTI-SARS-CoV-2 ANTIBODIES AND USES THEREOF
CN112979793B (en) * 2020-05-27 2022-02-11 江苏省疾病预防控制中心(江苏省公共卫生研究院) Antibodies to detect novel coronavirus
CN112898416B (en) * 2020-05-27 2022-02-11 江苏省疾病预防控制中心(江苏省公共卫生研究院) Binding protein of novel coronavirus NP protein and application thereof
CN111518203B (en) * 2020-05-27 2021-10-19 江苏省疾病预防控制中心(江苏省公共卫生研究院) Kit for detecting novel coronavirus
CN112898415B (en) * 2020-05-27 2021-12-10 江苏省疾病预防控制中心(江苏省公共卫生研究院) Antibody for detecting novel coronavirus and detection kit
CN112979790B (en) * 2020-05-27 2022-02-11 江苏省疾病预防控制中心(江苏省公共卫生研究院) Antibodies and use in detecting novel coronaviruses
CN111518202B (en) * 2020-05-27 2021-10-19 江苏省疾病预防控制中心(江苏省公共卫生研究院) Novel coronavirus antibodies and ELISA test kits for novel coronavirus antibodies
CN112979791B (en) * 2020-05-27 2021-12-10 江苏省疾病预防控制中心(江苏省公共卫生研究院) Antibodies against novel coronaviruses
WO2021242178A1 (en) * 2020-05-29 2021-12-02 National University Of Singapore A method, a system, an article, a kit and use thereof for biomolecule, bioorganelle, bioparticle, cell and microorganism detection
PH12022500028A1 (en) 2020-06-03 2024-05-06 Regeneron Pharma Methods for treating or preventing sars-cov-2 infections and covid -19 with anti-sars-cov-2 spike glycoprotein antibodies
CN113831409B (en) * 2020-06-08 2023-04-25 中国科学院深圳先进技术研究院 A kind of anti-SAR-COV-2 antibody or its antigen-binding fragment and application thereof
CN113896788B (en) * 2020-06-22 2023-05-23 中国科学院深圳先进技术研究院 anti-SAR-COV-2 (COVID-19) fully human monoclonal antibody and preparation method and application thereof
CN113480644B (en) * 2020-08-10 2022-09-16 南开大学 Anti-coronavirus antibody and application thereof
CN111909263B (en) * 2020-08-19 2022-10-11 重庆医科大学 New coronavirus RBD specific monoclonal antibody and application
CN111925443B (en) * 2020-08-19 2022-10-11 重庆医科大学 Novel coronavirus RBD-specific monoclonal antibodies and applications
CN116023477B (en) * 2020-08-19 2025-01-28 重庆医科大学 Novel coronavirus RBD-specific monoclonal antibodies and their applications
CN114989293B (en) * 2020-08-19 2023-10-17 重庆医科大学 COVID-19 RBD-specific monoclonal antibodies and applications
CN111925441B (en) * 2020-08-19 2022-10-04 重庆医科大学 Novel coronavirus RBD-specific monoclonal antibodies and applications
WO2022101839A1 (en) * 2020-11-12 2022-05-19 Cadila Healthcare Limited Anti-sars-cov-2 monoclonal antibodies and cocktail thereof
US11693011B2 (en) 2020-12-14 2023-07-04 Inbios International, Inc. Neutralizing antibody immunoassays
EP4304651A2 (en) * 2021-03-26 2024-01-17 Atreca, Inc. Antibodies to sars-cov-2
MX2023000578A (en) 2021-04-12 2023-04-26 Academia Sinica Improved coronavirus vaccine.
WO2022271884A2 (en) * 2021-06-22 2022-12-29 Twist Bioscience Corporation Methods and compositions relating to covid antibody epitopes
BR112024000744A2 (en) 2021-07-14 2024-04-30 Regeneron Pharma ANTI-SARS-COV-2 SPIKE GLYCOPROTEIN ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
WO2023048656A2 (en) * 2021-09-24 2023-03-30 Chulalongkorn University Human monoclonal antibodies against the receptor-binding domain of sars-cov-2 spike protein
TW202334429A (en) 2021-10-01 2023-09-01 中央研究院 Antibody specific to spike protein of sars-cov-2 and uses thereof
US20240400653A1 (en) * 2021-10-07 2024-12-05 Seqirus Pty Ltd Anti-sars-cov-2 antibodies and uses thereof i
CN118574846A (en) * 2022-03-30 2024-08-30 上海科技大学 Anti-neocrown nano antibody and application thereof
WO2024007013A2 (en) * 2022-06-30 2024-01-04 Modex Therapeutics, Inc. Anti-sars-cov-2 antigen binding polypeptides, polypeptide complexes and methods of use thereof
AU2024252371B2 (en) 2023-04-08 2026-02-12 Rock Biomedical Inc. Methods and compositions for dendritic cell targeting nano-delivery
AU2024255035B2 (en) 2023-04-08 2025-08-07 Rock Biomedical Inc. Methods and compositions for targeted delivery by polymersomes
WO2024238734A2 (en) 2023-05-17 2024-11-21 Rock Biomedical Inc. Mgat1 deficient cells and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2183667A1 (en) 1994-02-22 1995-08-24 Wayne A. Marasco Nucleic acid delivery system, method of synthesis and uses thereof
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
RU2398882C2 (en) 2004-07-22 2010-09-10 Эрасмус Юниверсити Медикал Сентр Роттердам METHOD OF PRODUCING ANTIGEN-BINDING Vh DOMAIN, APPLICATION THEREOF
SG169348A1 (en) 2006-01-25 2011-03-30 Univ Erasmus Medical Ct Generation of heavy-chain only antibodies in transgenic animals
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
EP2242768A4 (en) * 2008-01-17 2012-03-14 Humabs Llc CROSS-CONDUCTIVE HUMAN MONOCLONAL ANTIBODIES AGAINST SARS-VOC AND METHODS OF USE THEREOF
ES2613730T3 (en) 2008-12-18 2017-05-25 Erasmus University Medical Center Rotterdam Non-human transgenic animals expressing humanized antibodies and their use
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
AU2013328881B2 (en) * 2012-10-12 2018-03-15 Arizona Board Of Regents, On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
US9980470B2 (en) 2013-03-14 2018-05-29 Erasmus University Medical Center Antibody production
WO2014141192A1 (en) 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device
US9629801B2 (en) * 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
GB202004340D0 (en) 2020-05-06
GB202101720D0 (en) 2021-03-24
GB202015240D0 (en) 2020-11-11
AR121522A1 (en) 2022-06-08
WO2021180604A1 (en) 2021-09-16
US20220017606A1 (en) 2022-01-20
UY39118A (en) 2021-10-29
US20210340225A1 (en) 2021-11-04
TW202200612A (en) 2022-01-01
GB202003632D0 (en) 2020-04-29
WO2021180602A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
GB202013024D0 (en) Sars-Cov-2 (SARS2, COVID-19) antobodies
ES3055163T3 (en) Class ii, type ii crispr systems
GB2617658B (en) Class II, type V CRISPR systems
IL284800A (en) Methods, uses & compositions
GB202020310D0 (en) Sars-cov-2 antobodies
IL288864A (en) Treatment comprising sglt inhibitors, e.g. sglt 1/2 inhibitors
DK4027026T3 (en) Søm, særligt til anvendelse i et sømningsapparat
DK3702546T3 (en) Affaldsfrit, snitfrit sammensat træpanel til en træbygningskonstruktion
GB202005952D0 (en) Regalsystem, RegaLseitenwand und Seitenwandteil
GB201912021D0 (en) Methods, products & Uses relating thereto
GB202011508D0 (en) .
GB202216044D0 (en) Kissthestarzdesigns, kissthestars, petrasdigicity
GB202214460D0 (en) Tchaman-aijuhoh12circlexdoKSgachachatchamanaijuhoh12circlexdotMaZelizelizeliganjuYohchakukeiMoShoshoshoshuhshuhshuhtennaizi-neobey80,000XOnlyShosshoshoshuhshu
GB202214459D0 (en) tchaman-aijuhoh12circledotksgachachatchamanaijuhoh12circlexdotmazelizelizeliganjuyohchakukeimoshoshoshoshuhshuhshutennaizo-neobey80,000xonlyshoshoshoshuhshuhs
GB202114334D0 (en) Klucz oraz zestaw klucza i wkladki, zwlaszcza do otwierania i zamykania zamka
EP3699287A4 (en) Method for purifying 1,5-diaminopentane
GB201812663D0 (en) illimitably drive(ID),
GB202110151D0 (en) Saifety.ai
GB202114277D0 (en) Laptable.
GB202104380D0 (en) mamama400..
GB202104377D0 (en) Mamama400...
GB202104366D0 (en) Mamama400....
GB202013655D0 (en) .
GB202215049D0 (en) Shoshoshonaiqueteizo...........
GB202002241D0 (en) Mamana....

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)